Critical Limb Ischemia Classification and Therapeutic Angiogenesis
暂无分享,去创建一个
[1] A. Pockley,et al. VEGF and VEGF receptor expression in human chronic critical limb ischaemia. , 2004, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.
[2] R. Donnelly,et al. Therapeutic angiogenesis in peripheral arterial disease: can biotechnology produce an effective collateral circulation? , 2004, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.
[3] M. Salis,et al. Nerve growth factor supplementation reverses the impairment, induced by Type 1 diabetes, of hindlimb post-ischaemic recovery in mice , 2004, Diabetologia.
[4] R. Draghia‐Akli,et al. Insulin-like growth factor I plasmid therapy promotes in vivo angiogenesis. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[5] C. Cooper,et al. Evaluation and medical treatment of peripheral arterial disease , 2003, Current opinion in cardiology.
[6] R. Sarkar,et al. Overexpression of endothelial nitric oxide synthase increases skeletal muscle blood flow and oxygenation in severe rat hind limb ischemia. , 2003, Journal of vascular surgery.
[7] A. Bett,et al. Vascular endothelial growth factor stimulates angiogenesis without improving collateral blood flow following hindlimb ischemia in rabbits , 2003, Heart and Vessels.
[8] H. Johansson,et al. Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. , 2003, The Journal of clinical investigation.
[9] N. Ferrara,et al. The biology of VEGF and its receptors , 2003, Nature Medicine.
[10] P. Carmeliet. Angiogenesis in health and disease , 2003, Nature Medicine.
[11] Philippe Leboulch,et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2 , 2003, Nature Medicine.
[12] Lijun Li,et al. Neuropeptide Y: a new mediator linking sympathetic nerves, blood vessels and immune system? , 2003, Canadian journal of physiology and pharmacology.
[13] Z. Zukowska,et al. Neuropeptide Y: a novel mechanism for ischemic angiogenesis. , 2003, Trends in cardiovascular medicine.
[14] R. Kauppinen,et al. Fibroblast growth factor‐4 induces vascular permeability, angiogenesis, and arteriogenesis in a rabbit hind limb ischemia model , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[15] Lijun Li,et al. Dual role of dipeptidyl peptidase IV (DPP IV) in angiogenesis and vascular remodeling. , 2003, Advances in experimental medicine and biology.
[16] Y. Kan,et al. Adeno-associated viral vector-mediated gene transfer of VEGF normalizes skeletal muscle oxygen tension and induces arteriogenesis in ischemic rat hindlimb. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.
[17] W. Schaper,et al. Blood monocyte concentration is critical for enhancement of collateral artery growth. , 2002, American journal of physiology. Heart and circulatory physiology.
[18] K. Nakagawa,et al. Fibroblast Growth Factor-2 Gene Transfer Can Stimulate Hepatocyte Growth Factor Expression Irrespective of Hypoxia-Mediated Downregulation in Ischemic Limbs , 2002, Circulation research.
[19] C. Wright. Effects of vascular endothelial growth factor (VEGF)A and VEGFB gene transfer on vascular reserve in a conscious rabbit hindlimb ischaemia model , 2002, Clinical and experimental pharmacology & physiology.
[20] H. Matsubara,et al. Improvement of Collateral Perfusion and Regional Function by Implantation of Peripheral Blood Mononuclear Cells Into Ischemic Hibernating Myocardium , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[21] M. Salis,et al. Nerve Growth Factor Promotes Angiogenesis and Arteriogenesis in Ischemic Hindlimbs , 2002, Circulation.
[22] Masanori Hangai,et al. Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. , 2002, The American journal of pathology.
[23] G. Semenza. Signal transduction to hypoxia-inducible factor 1. , 2002, Biochemical pharmacology.
[24] R. Hynes. A reevaluation of integrins as regulators of angiogenesis , 2002, Nature Medicine.
[25] L. Chao,et al. Human Endothelial Nitric Oxide Synthase Gene Delivery Promotes Angiogenesis in a Rat Model of Hindlimb Ischemia , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[26] S. Ylä-Herttuala,et al. Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ , 2002, The journal of gene medicine.
[27] R. Lederman,et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial , 2002, The Lancet.
[28] C. Jackson. Matrix metalloproteinases and angiogenesis , 2002, Current opinion in nephrology and hypertension.
[29] U. Ikeda,et al. AAV-mediated VEGF gene transfer into skeletal muscle stimulates angiogenesis and improves blood flow in a rat hindlimb ischemia model. , 2002, Cardiovascular research.
[30] David A. Cheresh,et al. Role of integrins in cell invasion and migration , 2002, Nature Reviews Cancer.
[31] J. Isner,et al. Targeting Kinin B1 Receptor for Therapeutic Neovascularization , 2002, Circulation.
[32] P. McBride,et al. The significance of lower extremity peripheral arterial disease , 2002, Clinical cardiology.
[33] W. Pevec,et al. Functional outcome of new blood vessel growth into ischemic skeletal muscle. , 2001, Journal of vascular surgery.
[34] R. Sarkar,et al. Administration of adenoviral vectors induces gangrene in acutely ischemic rat hindlimbs: role of capsid protein-induced inflammation. , 2001, Journal of vascular surgery.
[35] C. Emanueli,et al. Targeting kinin receptors for the treatment of tissue ischaemia. , 2001, Trends in pharmacological sciences.
[36] S. Ylä-Herttuala,et al. Gene therapy for therapeutic angiogenesis in critically ischaemic lower limb – on the way to the clinic , 2001, European journal of clinical investigation.
[37] M. Castresana,et al. Reactive oxygen and NF-kappaB in VEGF-induced migration of human vascular smooth muscle cells. , 2001, Biochemical and biophysical research communications.
[38] H. Weltman,et al. Effect of nerve growth factor on endothelial cell biology: proliferation and adherence molecule expression on human dermal microvascular endothelial cells , 2001, Archives of Dermatological Research.
[39] L. Calzà,et al. Nerve growth factor control of neuronal expression of angiogenetic and vasoactive factors , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[40] H. A. Hartman,et al. Revascularization in the rabbit hindlimb: dissociation between capillary sprouting and arteriogenesis. , 2001, Cardiovascular research.
[41] Luigi Aloe,et al. Human monocyte/macrophages activate by exposure to LPS overexpress NGF and NGF receptors , 2001, Journal of Neuroimmunology.
[42] M. Salis,et al. Local Delivery of Human Tissue Kallikrein Gene Accelerates Spontaneous Angiogenesis in Mouse Model of Hindlimb Ischemia , 2001, Circulation.
[43] A. Tedgui,et al. Role of matrix metalloproteinases in blood flow-induced arterial enlargement: interaction with NO. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[44] I. Buschmann,et al. Vascular endothelial growth factor (VEGF) stimulates monocyte migration through endothelial monolayers via increased integrin expression. , 2000, European journal of cell biology.
[45] T. McCaffrey,et al. p75NTR Mediates Neurotrophin-Induced Apoptosis of Vascular Smooth Muscle Cells , 2000 .
[46] J. Garb,et al. Angiogenic therapy for the chronically ischemic lower limb in a rabbit model. , 2000, The Journal of surgical research.
[47] A. Luttun,et al. The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: Insights from genetic studies , 2000, Current atherosclerosis reports.
[48] J. Isner,et al. Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. , 2000, Circulation research.
[49] N. Glazer,et al. Angiopoietin-1 protects the adult vasculature against plasma leakage , 2000, Nature Medicine.
[50] P. Carmeliet. Mechanisms of angiogenesis and arteriogenesis , 2000, Nature Medicine.
[51] A. Lambiase,et al. Nerve growth factor promotes corneal healing: structural, biochemical, and molecular analyses of rat and human corneas. , 2000, Investigative ophthalmology & visual science.
[52] J. Isner,et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[53] J. Cooke,et al. Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. , 2000, Arteriosclerosis, Thrombosis and Vascular Biology.
[54] G. Tognoni,et al. Clinical Outcome and its Predictors in 1560 Patients with Critical Leg Ischaemia , 1999 .
[55] B. Zetter,et al. Vascular endothelial growth factor-induced migration of vascular smooth muscle cells in vitro. , 1999, Microvascular research.
[56] L. Chao,et al. Kallikrein gene delivery inhibits vascular smooth muscle cell growth and neointima formation in the rat artery after balloon angioplasty. , 1999, Hypertension.
[57] R. Busse,et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation , 1999, Nature.
[58] Y. Fujio,et al. Akt Mediates Cytoprotection of Endothelial Cells by Vascular Endothelial Growth Factor in an Anchorage-dependent Manner* , 1999, The Journal of Biological Chemistry.
[59] D. Hanahan,et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. , 1999, Genes & development.
[60] G. Yancopoulos,et al. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. , 1999, Genes & development.
[61] B. Hempstead,et al. NGF activates similar intracellular signaling pathways in vascular smooth muscle cells as PDGF-BB but elicits different biological responses. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[62] A. Samii,et al. Vascular endothelial growth factor expression in peripheral nerves and dorsal root ganglia in diabetic neuropathy in rats , 1999, Neuroscience Letters.
[63] J. Isner,et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. , 1999, The American journal of pathology.
[64] W. Pevec,et al. Regulation of new blood vessel growth into ischemic skeletal muscle. , 1998, Journal of vascular surgery.
[65] M. Cronin,et al. Peripheral neuropathy in transgenic diabetic mice: restoration of C-fiber function with human recombinant nerve growth factor. , 1998, Diabetes.
[66] M. Shibuya,et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[67] E. Karwatowska-Prokopczuk,et al. Mechanisms of vascular growth-promoting effects of neuropeptide Y: role of its inducible receptors , 1998, Regulatory Peptides.
[68] J. Garb,et al. Basic fibroblast growth factor stimulates angiogenesis in the hindlimb of hyperglycemic rats. , 1998, The Journal of surgical research.
[69] W. T. Chen,et al. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. , 1998, Circulation research.
[70] H. Granger,et al. B1 receptor involvement in the effect of bradykinin on venular endothelial cell proliferation and potentiation of FGF‐2 effects , 1998, British journal of pharmacology.
[71] R. Crystal,et al. Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion. , 1998, Journal of vascular surgery.
[72] H. Granger,et al. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. , 1998, American journal of physiology. Heart and circulatory physiology.
[73] P. Huang,et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. , 1998, The Journal of clinical investigation.
[74] Arno W. Hoes,et al. Peripheral arterial disease in the elderly: The Rotterdam Study. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[75] W. Schaper,et al. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. , 1998, The Journal of clinical investigation.
[76] A. Hajitou,et al. Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression. , 1997, Cancer research.
[77] J. Isner,et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[78] J. Herbert,et al. NGF exhibits a pro‐apoptotic activity for human vascular smooth muscle cells that is inhibited by TGFβ1 , 1997, FEBS letters.
[79] During,et al. Adeno-associated virus as a gene delivery system. , 1997, Advanced drug delivery reviews.
[80] T. Rosengart,et al. Therapeutic angiogenesis: a comparative study of the angiogenic potential of acidic fibroblast growth factor and heparin. , 1997, Journal of vascular surgery.
[81] Thomas N. Sato,et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.
[82] M. Dennis,et al. Regulation of mitogenesis by kinins in arterial smooth muscle cells. , 1997, The American journal of physiology.
[83] W. Schaper,et al. Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. , 1997, Circulation research.
[84] J. Wolfe,et al. Critical and subcritical ischaemia. , 1997, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.
[85] R Bicknell,et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. , 1997, The Journal of clinical investigation.
[86] W. Risau,et al. Mechanisms of angiogenesis , 1997, Nature.
[87] M. Koelemay,et al. The value of non-invasive techniques for the assessment of critical limb ischaemia. , 1997, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.
[88] James M. Wilson,et al. Recombinant adeno-associated virus for muscle directed gene therapy , 1997, Nature Medicine.
[89] B. Schölkens,et al. Different B1 kinin receptor expression and pharmacology in endothelial cells of different origins and species. , 1997, The Journal of pharmacology and experimental therapeutics.
[90] J. Smith,et al. Fibroblast growth factors and their receptors. , 1997, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[91] J. Isner,et al. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. , 1996, Circulation.
[92] M. Lohse,et al. Ligand-induced Phosphorylation/Dephosphorylation of the Endogenous Bradykinin B2 Receptor from Human Fibroblasts* , 1996, The Journal of Biological Chemistry.
[93] B. Byrne,et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[94] W. Schaper,et al. Molecular mechanisms of coronary collateral vessel growth. , 1996, Circulation research.
[95] J. Isner,et al. Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischemia. , 1996, Biochemical and biophysical research communications.
[96] B. Davidson,et al. Systemic delivery of the interleukin-1 receptor antagonist protein using a new strategy of direct adenoviral-mediated gene transfer to skeletal muscle capillary endothelium in the isolated rat hindlimb. , 1996, Human gene therapy.
[97] H. Granger,et al. Acidic and basic FGFs dilate arterioles of skeletal muscle through a NO-dependent mechanism. , 1996, The American journal of physiology.
[98] S. Bunting,et al. Vascular endothelial growth factor augments muscle blood flow and function in a rabbit model of chronic hindlimb ischemia. , 1996, Journal of cardiovascular pharmacology.
[99] J. Isner,et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. , 1995, Circulation.
[100] J. Slavin,et al. Fibroblast growth factors: at the heart of angiogenesis. , 1995, Cell biology international.
[101] J. Isner,et al. Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. , 1995, Journal of vascular surgery.
[102] Daniel Grandt,et al. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV , 1993, Regulatory Peptides.
[103] C. Soria,et al. Activation of the 92 kDa type IV collagenase by tissue kallikrein , 1993, Journal of cellular physiology.
[104] J. Wolfe,et al. Critical leg ischaemia: an appraisal of clinical definitions , 1993, The British journal of surgery.
[105] C. Wahlestedt,et al. Origin and Actions of Neuropeptide Y in the Cardiovascular System , 1993 .
[106] J. Garb,et al. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose-response effect of basic fibroblast growth factor. , 1992, Journal of vascular surgery.
[107] K. Bhoola,et al. Bioregulation of kinins: kallikreins, kininogens, and kininases. , 1992, Pharmacological reviews.
[108] S. Ahn. Endovascular surgery: current concepts and its importance to the vascular surgeon. , 1992, European journal of vascular surgery.
[109] J. Hall,et al. Bradykinin receptors: pharmacological properties and biological roles. , 1992, Pharmacology & therapeutics.
[110] D. Clement. Second European Consensus Document on chronic critical leg ischemia. , 1991, Circulation.
[111] D. Connolly,et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration , 1990, The Journal of experimental medicine.
[112] D. Goeddel,et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.
[113] P. Holstein,et al. The Ischaemic Leg: a Long-Term Follow-Up with Special Reference to the Predictive Value of the Systolic Digital Blood Pressure - Part II: After Arterial Reconstruction , 1989, The Thoracic and cardiovascular surgeon.
[114] D. Rifkin,et al. Processing, secretion, and biological properties of a novel growth factor of the fibroblast growth factor family with oncogenic potential , 1988, Molecular and cellular biology.
[115] E. Levine,et al. Human endothelial cells: use of heparin in cloning and long-term serial cultivation. , 1983, Science.
[116] D. Regoli,et al. Pharmacology of bradykinin and related kinins. , 1980, Advances in experimental medicine and biology.
[117] P. Gullino,et al. Role of prostaglandin E1 and copper in angiogenesis. , 1982, Journal of the National Cancer Institute.